Asymptomatic hyperuricemia following renal transplantation

Table 2 Studies of uric-acid-lowering therapy in renal allograft recipients

Ref.	Study population	Average follow-up	Intervention/outcome(s)	Main study findings
Perez-Ruiz et al[34]	279 renal allograft recipients with hyperuricemia	38.6 ± 18.4 mo	Allopurinol, benziodarone/ serum UA levels	Both drugs effective in lowering serum UA; benziodarone safer in patients on azathioprine
Numakura et al[11]	121 renal allograft recipients with and without hyperuricemia	Up to 10 yr, mean not reported	Allopurinol/eGFR, graft survival	Hyperuricemia associated with reduced eGFR, but graft survival similar in normo and hyperuricemic patients
Osadchuck et al[35]	108 renal allograft recipients (54 patients treated vs 54 controls)	2 yr	Allopurinol/Serum UA levels, eGFR, graft survival	Reduced serum UA, preservation of eGFR in allopurinol treated patients; no differences in graft survival and blood pressure
Sofue et al[36]	93 renal allograft recipients (42 normouricemic, 51 hyperuricemic, 26 treated, 25 not treated)	1 yr	Febuxostat/serum UA levels, eGFR	Serum UA lower and eGFR stable in patients treated with febuxostat
Tojimbara et al[38]	23 renal allograft recipients with hyperuricemia	12 ± 2 mo	Febuxostat/serum UA, eGFR	Serum UA lower after treatment with febuxostat; eGFR stable

UA: Uric acid; eGFR: Estimated glomerular filtration rate.